Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects. (28th January 2014)

• Record Type: Journal Article
• Authors: Beusterien, Kathleen; Grinspan, Jessica; Kuchuk, Iryna; Mazzarello, Sasha; Dent, Susan; Gertler, Stan; Bouganim, Nathaniel; Vandermeer, Lisa; Clemons, Mark
• Is Part Of: Oncologist. Volume 19:Number 2(2014)
• Page Start: 127
• Page End: 134
• Publication Date: 2014-01-28
• Subjects: Conjoint -- Preferences -- Breast cancer -- Side effects -- Tradeoffs; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2013-0359
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Objective: Our objective was to evaluate preferences associated with grade I/II and grade III/IV chemotherapy side effects among breast cancer patients receiving chemotherapy. We also assessed trade-offs that patients are willing to make between treatment side effects and the route and schedule of treatment administration. Methods: In this cross-sectional study, patients receiving chemotherapy for breast cancer completed a one-time Web survey. Conjoint analysis was used to elicit preferences for 17 grade I/II and III/IV side effects associated with available chemotherapies and regimens. In the analysis, the risk of each side effect was increased by 5%, holding all others constant, and the respective impact on patient preferences was identified. Results: A total of 102 women participated (mean age 54 ± 11). Among the grade I/II side effects, a 5% reduction in the risk of sensory neuropathy, nausea, and motor neuropathy had the highest impact on preferences. Among grade III/IV side effects, motor neuropathy, nausea/vomiting, and myalgia made the most difference. An oral twice-daily regimen was most preferred; however, patients were willing to receive an intravenous regimen relative to oral to avoid an increased risk of 5% in the majority of side effects. Avoiding an increased chance of grade III/IV motor neuropathy was associated with willingness to tolerate one of the least preferred administration schedules. Conclusion: This study identified relative preferences among both mild/moderate to severe side effects from the patient perspective. Patients appear to be willing to make trade-offs between side effects and different regimens. These findings may help to inform medical decision-making processes. Abstract : The objective of this study was to evaluate preferences associated with grade I/II and grade III/IV chemotherapy side effects among breast cancer patients receiving chemotherapy. This study also assessed trade-offs that patients are willing to make between treatment side effects and the route and schedule of treatment administration. Results identified relative preferences among both mild/moderate to severe side effects from the patient perspective; patients appear to be willing to make trade-offs between side effects and different regimens.